Long-term adherence to chronic disease treatments is challenging, with only about 50% adherence in developed nations, prompting a need for effective management strategies.
The study evaluated how satisfaction with the Flexig mHealth application influenced adherence to subcutaneous immunoglobulin therapy among French patients with chronic dysimmune diseases over two years.
Results showed a high adherence rate of 99.7% linked to good user satisfaction with Flexig, indicating that digital tools can significantly enhance treatment compliance for patients.